<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns="http://purl.org/rss/1.0/"><channel rdf:about="http://www.kjms-online.com/?rss=yes"><title>Kaohsiung Journal of Medical Sciences</title><description>Kaohsiung Journal of Medical Sciences RSS feed: Current Issue.    
 The Kaohsiung Journal of Medical Sciences , a peer-reviewed publication of  Kaohsiung 
Medical University , Taiwan, was established in 1985 to promote clinical and scientific research in the medical sciences 
in Taiwan, and to disseminate this research to the international community of medical and health care professionals. It is published 
monthly by Elsevier (Singapore) Pte Ltd.   </description><link>http://www.kjms-online.com/?rss=yes</link><dc:publisher>Elsevier Inc.</dc:publisher><dc:language>en</dc:language><dc:rights> © 2011 Published by Elsevier Inc.  </dc:rights><prism:publicationName>Kaohsiung Journal of Medical Sciences</prism:publicationName><prism:issn>1607-551X</prism:issn><prism:volume>28</prism:volume><prism:number>2</prism:number><prism:publicationDate>February 2012</prism:publicationDate><prism:copyright> © 2011 Published by Elsevier Inc.  </prism:copyright><prism:rightsAgent>healthpermissions@elsevier.com</prism:rightsAgent><items><rdf:Seq><rdf:li rdf:resource="http://www.kjms-online.com/article/PIIS1607551X11001495/abstract?rss=yes"/><rdf:li rdf:resource="http://www.kjms-online.com/article/PIIS1607551X11002427/abstract?rss=yes"/><rdf:li rdf:resource="http://www.kjms-online.com/article/PIIS1607551X11002294/abstract?rss=yes"/><rdf:li rdf:resource="http://www.kjms-online.com/article/PIIS1607551X11002543/abstract?rss=yes"/><rdf:li rdf:resource="http://www.kjms-online.com/article/PIIS1607551X11002531/abstract?rss=yes"/><rdf:li rdf:resource="http://www.kjms-online.com/article/PIIS1607551X1100252X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.kjms-online.com/article/PIIS1607551X11002385/abstract?rss=yes"/><rdf:li rdf:resource="http://www.kjms-online.com/article/PIIS1607551X11001483/abstract?rss=yes"/><rdf:li rdf:resource="http://www.kjms-online.com/article/PIIS1607551X11002518/abstract?rss=yes"/><rdf:li rdf:resource="http://www.kjms-online.com/article/PIIS1607551X11002932/abstract?rss=yes"/></rdf:Seq></items></channel><item rdf:about="http://www.kjms-online.com/article/PIIS1607551X11001495/abstract?rss=yes"><title>Stem cells in human normal endometrium and endometrial cancer cells: Characterization of side population cells</title><link>http://www.kjms-online.com/article/PIIS1607551X11001495/abstract?rss=yes</link><description>Abstract: Recently, adult stem cells have been identified in several mature tissues. The human endometrium is responsive to sex steroid hormone. It undergoes extraordinary growth in a cyclic manner and is shed and regenerated throughout a woman’s lifetime. It has been proposed that the human endometrium may contain a population of stem cells, which are responsible for its remarkable regenerative ability. It is also suggested that stem-like cells exist in cancer tissues. Stem-like cell subpopulations, referred to as “side population” (SP) cells, have been identified in several tissues and tumors based on their ability to efflux the fluorescent dye Hoechst 33342. Recently, we isolated and characterized the SP cells in normal human endometrium and in an endometrial cancer (EC) cell line. Endometrial SP cells can function as progenitor cells. EC SP cells show the following: (1) reductions in the expression levels of differentiation markers; (2) long-term repopulating properties; (3) self-renewal capacity; (4) enhancement of migration and podia formation; (5) enhancement of tumorigenicity; and (6) bipotent developmental potential (tumor cells and stroma-like cells), suggesting that these SP cells have cancer stem-like cell features. We review the articles that show the presence of stem cells in normal endometrium and EC cells and demonstrate the results of our studies.</description><dc:title>Stem cells in human normal endometrium and endometrial cancer cells: Characterization of side population cells</dc:title><dc:creator>Kiyoko Kato</dc:creator><dc:identifier>10.1016/j.kjms.2011.06.028</dc:identifier><dc:source>Kaohsiung Journal of Medical Sciences 28, 2 (2012)</dc:source><dc:date>2012-01-25</dc:date><prism:publicationName>Kaohsiung Journal of Medical Sciences</prism:publicationName><prism:publicationDate>2012-01-25</prism:publicationDate><prism:volume>28</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1607-551X(12)X0003-2</prism:issueIdentifier><prism:section>Review Article</prism:section><prism:startingPage>63</prism:startingPage><prism:endingPage>71</prism:endingPage></item><item rdf:about="http://www.kjms-online.com/article/PIIS1607551X11002427/abstract?rss=yes"><title>Effect of the endothelin receptor antagonist tezosentan on alpha-naphthylthiourea-induced lung injury in rats</title><link>http://www.kjms-online.com/article/PIIS1607551X11002427/abstract?rss=yes</link><description>Abstract: Acute lung injury is an inflammatory syndrome that increases the permeability of the blood-gas barrier, resulting in high morbidity and mortality. Despite intensive research, treatment options remain limited. We investigated the protective efficacy of tezosentan, a novel, dual endothelin receptor antagonist, in an experimental model of alpha-naphthylthiourea (ANTU)-induced acute lung injury in rats. ANTU was intraperitoneally (i.p.) injected into rats at a dose of 10 mg/kg. Tezosentan was injected 30 minutes before ANTU was subcutaneously (s.c.) injected at doses of 2, 10, or 30 mg/kg, 60 minutes before ANTU was injected at doses of 2, 10, or 30 mg/kg (i.p.), and 90 minutes before ANTU at a dose of 10 mg/kg (i.p.). Four hours later, the lung weight/body weight (LW/BW) ratio and pleural effusion (PE) were measured. When injected 30 minutes before ANTU at doses of 2, 10, or 30 mg/kg (s.c.), tezosentan had no effect on lung pathology. When injected 60 minutes before ANTU at doses of 2, 10, or 30 mg/kg (i.p.) or 90 minutes before ANTU (10 mg/kg, i.p.), tezosentan significantly decreased the PE/BW ratio and had a prophylactic effect on PE formation at all doses. Therefore, tezosentan may attenuate lung injury. Furthermore, its acute and inhibitory effects on fluid accumulation were more effective in the pleural cavity than in the interstitial compartment in this experimental model.</description><dc:title>Effect of the endothelin receptor antagonist tezosentan on alpha-naphthylthiourea-induced lung injury in rats</dc:title><dc:creator>Figen Atalay, Gamze Yurdakan, Emine Yilmaz-Sipahi</dc:creator><dc:identifier>10.1016/j.kjms.2011.10.019</dc:identifier><dc:source>Kaohsiung Journal of Medical Sciences 28, 2 (2012)</dc:source><dc:date>2012-01-16</dc:date><prism:publicationName>Kaohsiung Journal of Medical Sciences</prism:publicationName><prism:publicationDate>2012-01-16</prism:publicationDate><prism:volume>28</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1607-551X(12)X0003-2</prism:issueIdentifier><prism:section>Original Articles</prism:section><prism:startingPage>72</prism:startingPage><prism:endingPage>78</prism:endingPage></item><item rdf:about="http://www.kjms-online.com/article/PIIS1607551X11002294/abstract?rss=yes"><title>Essentiality of HIV testing and education for effective HIV control in the national pilot harm reduction program: The Taiwan experience</title><link>http://www.kjms-online.com/article/PIIS1607551X11002294/abstract?rss=yes</link><description>Abstract: In 2005, a national pilot harm reduction program (PHRP), which mainly included a methadone maintenance treatment program (MMTP) and a needle/syringe exchange program (NSP), was implemented in Taiwan. We conducted this study to evaluate the effectiveness of harm reduction measures on HIV control among injecting drug users (IDUs) between PHRP and nonPHRP. The data on HIV, collected from incumbent Taiwanese authorities, were analyzed for their associations, risk and protective factors with PHRP measures. While the monthly HIV incidences did not show significant differences before and after PHRP in the four areas with PHRP (Taipei City, Taipei County, Taoyuan County and Tainan County), a significant increase in the HIV incidence was found in the 21 areas without PHRP. Hence, the implementation of the PHRP did result in a significant difference in the monthly HIV incidence between areas with and without the PHRP. Mandatory HIV testing was significantly associated with the HIV incidence according to the generalized estimation equations (GEE) model. With adjustments of time period and area with PHRP, and urban area, protective factors associated with HIV incidence were: educational materials, condoms, dilution water, and alcohol sponges/swabs. MMTP contributed to a higher HIV incidence, probably due to the concurrent HIV testing upon admission. Since HIV testing was not required in the NSP, the HIV testing-dependent MMTP may explain the association of the PHRP intervention and an increased HIV incidence. In summary, HIV testing and education were essential for effective HIV control upon implementing the PHRP.</description><dc:title>Essentiality of HIV testing and education for effective HIV control in the national pilot harm reduction program: The Taiwan experience</dc:title><dc:creator>Hsin-Ya Lee, Yi-Hsin Yang, Wen-Jing Yu, Lien-Wen Su, Tsang-Yaw Lin, Hsien-Jane Chiu, Hsin-Pei Tang, Chien-Yang Lin, Ryh-Nan Pan, Jih-Heng Li</dc:creator><dc:identifier>10.1016/j.kjms.2011.10.006</dc:identifier><dc:source>Kaohsiung Journal of Medical Sciences 28, 2 (2012)</dc:source><dc:date>2012-01-16</dc:date><prism:publicationName>Kaohsiung Journal of Medical Sciences</prism:publicationName><prism:publicationDate>2012-01-16</prism:publicationDate><prism:volume>28</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1607-551X(12)X0003-2</prism:issueIdentifier><prism:section>Original Articles</prism:section><prism:startingPage>79</prism:startingPage><prism:endingPage>85</prism:endingPage></item><item rdf:about="http://www.kjms-online.com/article/PIIS1607551X11002543/abstract?rss=yes"><title>Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients</title><link>http://www.kjms-online.com/article/PIIS1607551X11002543/abstract?rss=yes</link><description>Abstract: Positive serum antinuclear antibody (ANA) is not infrequent in chronic hepatitis C virus (HCV)-infected patients. This prospective study evaluated the impact of ANA on the response to and safety of peginterferon/ribavirin combination therapy for chronic hepatitis C patients in clinical practice. We enrolled 243 consecutive patients who were treated with a 24-week regimen of peginterferon-α plus ribavirin, with a 24-week follow-up period. ANA titer was determined before antiviral treatment. The primary end-point was sustained virological response (SVR), defined as HCV RNA &lt;50 IU/mL throughout the follow-up period. Overall, 187 (77.0%) patients experienced a SVR. In the 105-patient HCV genotype non-1 group, patients with ANA titer ≥1:80 had a significantly lower SVR rate than those with ANA titer &lt;1:80 (67.7% vs. 95.8%, respectively, p = 0.013). In contrast, in the 138-patient HCV genotype 1 group, the SVR rate did not differ between patients with and without ANA titer ≥1:80. Multivariate regressive analyses showed that ANA ≥1:80, age and HCV RNA levels were independent factors associated with SVR in HCV genotype non-1 patients; whereas HCV RNA levels and hepatic fibrosis were prognostic predictors of SVR in HCV genotype 1 patients. The frequencies of adverse events were similar between patients with and without ANA seropositivity. Peginterferon/ribavirin combination therapy is effective and safe in ANA-positive chronic hepatitis C patients. A high ANA titer was a negative prognostic factor for treatment response in HCV genotype non-1 patients.</description><dc:title>Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients</dc:title><dc:creator>Ming-Yen Hsieh, Chia-Yen Dai, Li-Po Lee, Jee-Fu Huang, Wan-Long Chuang, Nai-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Ming-Lung Yu</dc:creator><dc:identifier>10.1016/j.kjms.2011.10.031</dc:identifier><dc:source>Kaohsiung Journal of Medical Sciences 28, 2 (2012)</dc:source><dc:date>2012-01-24</dc:date><prism:publicationName>Kaohsiung Journal of Medical Sciences</prism:publicationName><prism:publicationDate>2012-01-24</prism:publicationDate><prism:volume>28</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1607-551X(12)X0003-2</prism:issueIdentifier><prism:section>Original Articles</prism:section><prism:startingPage>86</prism:startingPage><prism:endingPage>93</prism:endingPage></item><item rdf:about="http://www.kjms-online.com/article/PIIS1607551X11002531/abstract?rss=yes"><title>The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients</title><link>http://www.kjms-online.com/article/PIIS1607551X11002531/abstract?rss=yes</link><description>Abstract: This study investigated the differences in clinical and laboratory features as well as treatment response in 70 outpatients with macroprolactinemia and monomeric hyperprolactinemia treated with dopamine agonists. After precipitation of the patients’ serum samples with poly-ethylene-glycol (PEG), serum prolactin (PRL) levels were measured. We also measured serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol for women and testosterone for men. Clinical symptoms and signs were recorded. All patients received brain magnetic resonance imaging (MRI). After excluding patients with macroadenoma, 66 patients were treated with the dopamine agonist cabergoline. After 1 year, the clinical responses to cabergoline were recorded and PRL levels measured. Of the initial 70 patients with hyperprolactinemia, 15 patients (21.4%) were found to have macroprolactinemia, while the rest had monomeric hyperprolactinemia. The two groups did not differ with regard to galactorrhea, menstrual disturbances or impotence. There were no significant group differences in serum LH, FSH, estradiol or testosterone levels. Patients with macroprolactinemia, however, had a significantly lower infertility rate than those with true hyperprolactinemia (6.7% vs. 32.7%, p=0.005). A greater percentage of macroprolactinemic patients had normal MRI pituitary images than those with hyperprolactinemia (73.3% vs. 34.5%, p=0.029). Compared to those with true hyperprolactinemia, patients with macroprolactinemia were found to have no significant changes in clinical features and PRL levels after 1 year of cabergoline therapy (after PEG precipitation, pre- and post-PRL levels: 59.3±100.2 to 13.8±9.5ng/mL vs. 6.1±5.3 to 5.1±4.3ng/mL, p=0.002). In conclusion, while macroprolactinemia is a common cause of hyperprolactinemia, many clinical and laboratory features cannot be used reliably to differentiate macroprolactinemia from true hyperprolactinemia. Routine screening for all hyperprolactinemic sera with PEG might prevent the unnecessary use of image studies and medical treatments for people with hyperprolactinemia.</description><dc:title>The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients</dc:title><dc:creator>Chih-Chin Lu, Ching-Jung Hsieh</dc:creator><dc:identifier>10.1016/j.kjms.2011.10.030</dc:identifier><dc:source>Kaohsiung Journal of Medical Sciences 28, 2 (2012)</dc:source><dc:date>2012-01-16</dc:date><prism:publicationName>Kaohsiung Journal of Medical Sciences</prism:publicationName><prism:publicationDate>2012-01-16</prism:publicationDate><prism:volume>28</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1607-551X(12)X0003-2</prism:issueIdentifier><prism:section>Original Articles</prism:section><prism:startingPage>94</prism:startingPage><prism:endingPage>99</prism:endingPage></item><item rdf:about="http://www.kjms-online.com/article/PIIS1607551X1100252X/abstract?rss=yes"><title>Minimal invasive pyeloplasty technique with vertical surgical approach: An alternative to laparoscopic pyeloplasty</title><link>http://www.kjms-online.com/article/PIIS1607551X1100252X/abstract?rss=yes</link><description>Abstract: This retrospective clinical study presents pyeloplasty results following a muscle-splitting dissection, with mini-flank incision, using instruments held in a vertical position. Between 2004 and 2010, dismembered pyeloplasty (Anderson-Hynes) was performed in 37 cases (32 males and 5 females) with an average age of 26 years (range, 20–56 years). The technique was carried out through a window opened by separating the lateral abdominal muscles. Operation duration, length of incision, postoperative pain, complications, and radiological and clinical results were discussed. The operation duration was between 50 and 90 minutes (average=65 minutes), the incisional length 5 and 7cm (average=5.2cm), and visual pain scale was 4.1±3.1 and 3.3±3.4 at 4 and 24 hours after the operation, respectively. The duration of hospitalization was between 30 and 120 hours (average=42 hours). In a retrospective analysis of our study, one case was reoperated on, following recurrence with obstruction, there were 9 cases with prolonged dilation in response to diuretics and 29 cases with complete recovery. Pyeloplasty operations, with a vertical surgical approach through smaller incisions and muscle separation, offered shorter periods of hospitalization, less postoperative pain, acceptable cosmetic results and higher rates of functional recovery.</description><dc:title>Minimal invasive pyeloplasty technique with vertical surgical approach: An alternative to laparoscopic pyeloplasty</dc:title><dc:creator>Coşkun Şahin, Mehmet Kalkan, Hakkı Uzun</dc:creator><dc:identifier>10.1016/j.kjms.2011.10.029</dc:identifier><dc:source>Kaohsiung Journal of Medical Sciences 28, 2 (2012)</dc:source><dc:date>2012-01-16</dc:date><prism:publicationName>Kaohsiung Journal of Medical Sciences</prism:publicationName><prism:publicationDate>2012-01-16</prism:publicationDate><prism:volume>28</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1607-551X(12)X0003-2</prism:issueIdentifier><prism:section>Original Articles</prism:section><prism:startingPage>100</prism:startingPage><prism:endingPage>104</prism:endingPage></item><item rdf:about="http://www.kjms-online.com/article/PIIS1607551X11002385/abstract?rss=yes"><title>Effects of individual resilience intervention on indigenous people who experienced Typhoon Morkot in Taiwan</title><link>http://www.kjms-online.com/article/PIIS1607551X11002385/abstract?rss=yes</link><description>Abstract: In 2009, Typhoon Morakot struck Taiwan and caused serious harm to the indigenous peoples living in the southern mountainous regions. The objective of this study is to examine the effects of and the factors involved in individual resilience intervention of typhoon victims. Quantitative research was performed from October 2009 through September 2010. Purposive sampling yielded 77 indigenous persons who were willing to serve as participants in this study. These participants all maintained legal or actual residence in the areas of Kaohsiung that were affected by the typhoon. An individual resilience intervention program was implemented. The findings show the following: (1) after completing the individual resilience intervention program, the participants had higher individual resilience scores than before participating in the intervention program; and (2) individual resilience scores were significantly affected by residency after the typhoon. These findings suggest that an individual resilience intervention program is a useful approach that can be used to enhance the individual resilience of a victim and that professionals should pay more attention to victims who have to leave their hometowns after disasters.</description><dc:title>Effects of individual resilience intervention on indigenous people who experienced Typhoon Morkot in Taiwan</dc:title><dc:creator>Su-Fen Cheng, Chi-Wei Cheng, Wen-Chung Hsieh, Meng-Chun Chi, Szu-Ju Lin, Yi-Ting Liao</dc:creator><dc:identifier>10.1016/j.kjms.2011.10.015</dc:identifier><dc:source>Kaohsiung Journal of Medical Sciences 28, 2 (2012)</dc:source><dc:date>2012-01-27</dc:date><prism:publicationName>Kaohsiung Journal of Medical Sciences</prism:publicationName><prism:publicationDate>2012-01-27</prism:publicationDate><prism:volume>28</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1607-551X(12)X0003-2</prism:issueIdentifier><prism:section>Original Articles</prism:section><prism:startingPage>105</prism:startingPage><prism:endingPage>110</prism:endingPage></item><item rdf:about="http://www.kjms-online.com/article/PIIS1607551X11001483/abstract?rss=yes"><title>Enterococcus hirae-related acute pyelonephritis and cholangitis with bacteremia: An unusual infection in humans</title><link>http://www.kjms-online.com/article/PIIS1607551X11001483/abstract?rss=yes</link><description>Abstract: Very few reports are available from the literature related to Enterococcus hirae infection in humans, which is more frequently seen in animals and birds. We report two patients with E hirae bacteremia caused by acute pyelonephritis and acute cholangitis. The clinical courses have been smooth on use of sensitive antibiotic therapy. In both cases, the primary sources and portals of entry are clearly identified.</description><dc:title>Enterococcus hirae-related acute pyelonephritis and cholangitis with bacteremia: An unusual infection in humans</dc:title><dc:creator>Tze-Sian Chan, Min-Shung Wu, Fat-Moon Suk, Chun-Nan Chen, Yung-Fa Chen, Yen-Hui Hou, Gi-Shih Lien</dc:creator><dc:identifier>10.1016/j.kjms.2011.06.027</dc:identifier><dc:source>Kaohsiung Journal of Medical Sciences 28, 2 (2012)</dc:source><dc:date>2011-09-12</dc:date><prism:publicationName>Kaohsiung Journal of Medical Sciences</prism:publicationName><prism:publicationDate>2011-09-12</prism:publicationDate><prism:volume>28</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1607-551X(12)X0003-2</prism:issueIdentifier><prism:section>Case Reports</prism:section><prism:startingPage>111</prism:startingPage><prism:endingPage>114</prism:endingPage></item><item rdf:about="http://www.kjms-online.com/article/PIIS1607551X11002518/abstract?rss=yes"><title>Primary small cell carcinoma of the lesser omentum</title><link>http://www.kjms-online.com/article/PIIS1607551X11002518/abstract?rss=yes</link><description>Abstract: Although pulmonary small cell carcinoma (SCC) is seen frequently, SCC that originates from the extrapulmonary organs is extremely rare. We herein report a case of a SCC located in the lesser omentum. A 61-year-old male was admitted to our department due to intermittent epigastralgia for 2 months. Ultrasonography (US) revealed an irregular hypoechoic mass measuring about 58 mm × 50 mm × 45 mm under the left lobe of the liver. Magnetic resonance imaging (MRI) was performed to verify the irregular mass with T1- and T2- weighted images between the left lobe of liver and the stomach. At laparotomy, the well-circumscribed neoplasm was found in the lesser omentum, and the fundus of the neoplasm was located in the root of left gastric artery. Intraoperative microscopic evaluation of frozen sections revealed malignancy of the lesser omentum. Resection of the neoplasm was performed, and the combined resection of the vagal nerve was also performed for the partial adhesion. Pyloroplasty was performed for avoiding delayed gastric emptying caused by combined resection of vagal nerve. The lymph nodes dissection at lesser curvature and right cardia was also performed with a negative result. Based on the histological findings, the final diagnosis of primary lesser omental SCC was confirmed. The pathologic staging showed locoregional disease.</description><dc:title>Primary small cell carcinoma of the lesser omentum</dc:title><dc:creator>Ji-Feng Feng, Yi-He Guo, Wen-You Chen, Da-Feng Chen, Jing Liu</dc:creator><dc:identifier>10.1016/j.kjms.2011.10.028</dc:identifier><dc:source>Kaohsiung Journal of Medical Sciences 28, 2 (2012)</dc:source><dc:date>2012-01-16</dc:date><prism:publicationName>Kaohsiung Journal of Medical Sciences</prism:publicationName><prism:publicationDate>2012-01-16</prism:publicationDate><prism:volume>28</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1607-551X(12)X0003-2</prism:issueIdentifier><prism:section>Case Reports</prism:section><prism:startingPage>115</prism:startingPage><prism:endingPage>119</prism:endingPage></item><item rdf:about="http://www.kjms-online.com/article/PIIS1607551X11002932/abstract?rss=yes"><title>Jejunal undifferentiated spindle cell sarcoma with glossal metastasis</title><link>http://www.kjms-online.com/article/PIIS1607551X11002932/abstract?rss=yes</link><description>Spindle cell sarcomas, derived from primitive mesenchymal cells, represent 47.9% of all adult soft tissue sarcomas . They can be classified into malignant fibrous histiocytomas, leiomyosarcomas, neurosarcomas, fibrosarcoma, synovial sarcomas, hemangiopericytomas, and undifferentiated sarcoma . Of these cancers, 13.6% are located in the retroperitoneal space, intraabdominal area and pelvis, and 10.4% within the head and neck area . Here we describe a rare case with spindle cell sarcoma involving both jejunum and tongue.</description><dc:title>Jejunal undifferentiated spindle cell sarcoma with glossal metastasis</dc:title><dc:creator>Wei-Han Cheng, Jiann-Jy Chen, Yung-An Tsou, Guan-Chin Tseng</dc:creator><dc:identifier>10.1016/j.kjms.2011.12.001</dc:identifier><dc:source>Kaohsiung Journal of Medical Sciences 28, 2 (2012)</dc:source><dc:date>2012-01-16</dc:date><prism:publicationName>Kaohsiung Journal of Medical Sciences</prism:publicationName><prism:publicationDate>2012-01-16</prism:publicationDate><prism:volume>28</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1607-551X(12)X0003-2</prism:issueIdentifier><prism:section>Letter to the Editor</prism:section><prism:startingPage>120</prism:startingPage><prism:endingPage>121</prism:endingPage></item></rdf:RDF>
